0001104659-15-007835.txt : 20150209 0001104659-15-007835.hdr.sgml : 20150209 20150209163747 ACCESSION NUMBER: 0001104659-15-007835 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150205 FILED AS OF DATE: 20150209 DATE AS OF CHANGE: 20150209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rogus Joseph J CENTRAL INDEX KEY: 0001299691 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 15589031 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE STREET 2: 3RD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 a4.xml 4 X0306 4 2015-02-05 0 0000890465 NPS PHARMACEUTICALS INC NPSP 0001299691 Rogus Joseph J 550 HILLS DRIVE BEDMINSTER NJ 07921 0 1 0 0 SVP, GTO & Supply Chain Mngmt Common Stock 2015-02-05 4 M 0 16875 8.25 A 37026 D Common Stock 2015-02-05 4 M 0 11434 8.23 A 48460 D Common Stock 2015-02-05 4 M 0 4313 3.34 A 52773 D Common Stock 2015-02-05 4 S 0 32622 45.8968 D 20151 D Employee Stock Options (right to buy) 8.25 2015-02-05 4 M 0 16875 0 D 2021-02-17 Common Stock 16875 2813 D Employee Stock Options (right to buy) 8.23 2015-02-05 4 M 0 11434 0 D 2023-02-13 Common Stock 11434 14702 D Employee Stock Options (right to buy) 3.34 2015-02-05 4 M 0 4313 0 D 2020-02-19 Common Stock 4313 69738 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.89 to $45.93, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. On February 17, 2011, the reporting person received a grant of 45,000 stock options under the Issuer's 1998 Stock Option Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On February 13, 2013, the reporting person received a grant of 26,136 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On February 19, 2010, the reporting person was granted options to purchase shares of common stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. /s/ Joseph J. Rogus, by Jill Thompson as attorney-in-fact 2015-02-09